Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles

Objective Genetic and immunological data indicate that inflammatory bowel disease (IBD) are characterized by specific inflammatory protein profiles. However, the serum proteome of IBD is still to be defined. We aimed to characterize the inflammatory serum protein profiles of Crohn’s disease (CD) and ulcerative colitis (UC), using the novel proximity extension assay. Methods A panel of 91 inflammatory proteins were quantified in a discovery cohort of CD (n = 54), UC patients (n = 54), and healthy controls (HCs; n = 54). We performed univariate analyses by t-test, with false discovery rate correction. A sparse partial least-squares (sPLS) approach was used to identify additional discriminative proteins. The results were validated in a replication cohort. Results By univariate analysis, 17 proteins were identified with significantly different abundances in CD and HCs, and 12 when comparing UC and HCs. Additionally, 64 and 45 discriminant candidate proteins, respectively, were identified with the multivariate approach. Correspondingly, significant cross-validation error rates of 0.12 and 0.19 were observed in the discovery cohort. Only FGF-19 was identified from univariate comparisons of CD and UC, but 37 additional discriminant candidates were identified using the multivariate approach. The observed cross-validation error rate for CD vs. UC remained significant when restricting the analyses to patients in clinical remission. Using univariate comparisons, 16 of 17 CD-associated proteins and 8 of 12 UC-associated proteins were validated in the replication cohort. The area under the curve for CD and UC was 0.96 and 0.92, respectively, when the sPLS model from the discovery cohort was applied to the replication cohort. Conclusions By using the novel PEA method and a panel of inflammatory proteins, we identified proteins with significantly different quantities in CD patients and UC patients compared to HCs. Our data highlight the potential of the serum IBD proteome as a source for identification of future diagnostic biomarkers.

[1]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[2]  J. Rhodes,et al.  Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD? , 2016, Gut.

[3]  Tariq Ahmad,et al.  Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study , 2016, The Lancet.

[4]  R. Price,et al.  Chemokine and cytokine levels in inflammatory bowel disease patients. , 2016, Cytokine.

[5]  C. Fiocchi,et al.  Immunopathogenesis of IBD: current state of the art , 2016, Nature Reviews Gastroenterology &Hepatology.

[6]  R. Leong,et al.  Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective* , 2015, Molecular & Cellular Proteomics.

[7]  Samir A. Shah,et al.  Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study , 2015, Inflammatory bowel diseases.

[8]  C. Abraham,et al.  A TPL2 (MAP3K8) disease-risk polymorphism increases TPL2 expression thereby leading to increased pattern recognition receptor-initiated caspase-1 and caspase-8 activation, signalling and cytokine secretion , 2015, Gut.

[9]  S. Pellom,et al.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn’s Colitides , 2015, Clinical medicine insights. Gastroenterology.

[10]  R. Gearry,et al.  Disease Activity Assessment in IBD: Clinical Indices and Biomarkers Fail to Predict Endoscopic Remission , 2015, Inflammatory bowel diseases.

[11]  J. Walters,et al.  Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19. , 2015, Journal of Crohn's & colitis.

[12]  M. D’Amato,et al.  The history of genetics in inflammatory bowel disease , 2014, Annals of gastroenterology.

[13]  K. Sworczak,et al.  Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis. , 2014, Journal of Crohn's & colitis.

[14]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[15]  S. Brand,et al.  Oncostatin M Mediates STAT3-Dependent Intestinal Epithelial Restitution via Increased Cell Proliferation, Decreased Apoptosis and Upregulation of SERPIN Family Members , 2014, PloS one.

[16]  Dawn B. Beaulieu,et al.  High-Throughput Multi-Analyte Luminex Profiling Implicates Eotaxin-1 in Ulcerative Colitis , 2013, PloS one.

[17]  M. D’Amato,et al.  Polymorphism in the Retinoic Acid Metabolizing Enzyme CYP26B1 and the Development of Crohn’s Disease , 2013, PloS one.

[18]  D. Foell,et al.  Improving Relapse Prediction in Inflammatory Bowel Disease by Neutrophil-Derived S100A12 , 2013, Inflammatory bowel diseases.

[19]  Tahir Mehmood,et al.  Improving stability and understandability of genotype-phenotype mapping in Saccharomyces using regularized variable selection in L-PLS regression , 2012, BMC Bioinformatics.

[20]  J. Muntané,et al.  Role of serum cytokine profile in ulcerative colitis assessment , 2012, Inflammatory bowel diseases.

[21]  Yuefan Zhang,et al.  Comparative proteomics analysis of serum proteins in ulcerative colitis patients , 2012, Molecular Biology Reports.

[22]  Sanjeeva Srivastava,et al.  Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead , 2011, Proteomics.

[23]  Philippe Besse,et al.  Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems , 2011, BMC Bioinformatics.

[24]  D. Männel,et al.  Neutralization of LIGHT ameliorates acute dextran sodium sulphate‐induced intestinal inflammation , 2009, Immunology.

[25]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[26]  Faecal S 100 A 12 as a non-invasivemarker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2008 .

[27]  M. Lacher,et al.  Association of a CXCL9 polymorphism with pediatric Crohn's disease. , 2007, Biochemical and biophysical research communications.

[28]  S. Kliewer,et al.  Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21* , 2007, Journal of Biological Chemistry.

[29]  D. Foell,et al.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2007, Gut.

[30]  P. Geurts,et al.  Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. , 2007, Biochemical pharmacology.

[31]  L. Eriksson.  Multi- and megavariate data analysis , 2006 .

[32]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[33]  H. Tilg,et al.  The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss , 2005, Gut.

[34]  D. Hoover,et al.  Many chemokines including CCL20/MIP‐3α display antimicrobial activity , 2003 .

[35]  D. Foell,et al.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease , 2003, Gut.

[36]  E. Kunkel,et al.  A Common Mucosal Chemokine (Mucosae-Associated Epithelial Chemokine/CCL28) Selectively Attracts IgA Plasmablasts 1 , 2003, The Journal of Immunology.

[37]  D. Hoover,et al.  Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. , 2003, Journal of leukocyte biology.

[38]  J. Malm,et al.  Increased presence of cells containing transforming growth factor alpha (TGF‐&agr;) in ulcerative colitis, both during active inflammation and in remission , 2000, European journal of gastroenterology & hepatology.

[39]  V. Dessirier,et al.  Transforming Growth Factor-α and Epidermal Growth Factor Receptor in Colonic Mucosa in Active and Inactive Inflammatory Bowel Disease , 2000, Growth factors.

[40]  V. Dessirier,et al.  Transforming growth factor-alpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease. , 2000, Growth factors.

[41]  Hellēnikē Gastrenterologikē Hetaireia.  Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology. , 2000 .

[42]  Han van de Waterbeemd,et al.  Chemometric methods in molecular design , 1995 .

[43]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[44]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[45]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[46]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.